Perigon Wealth Management’s Cognition Therapeutics CGTX Stock Holding History

Perigon Wealth Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-223,500	Closed	-$322K	–	843
2023 Q3	$322K	Hold	223,500	–	–	0.01%	563
2023 Q2	$409K	Sell	223,500 -1,500	-0.7%	-$3.17K	0.02%	512
2023 Q1	$446K	Sell	225,000 -1,000	-0.4%	-$1.91K	0.03%	420
2022 Q4	$475K	Buy	226,000 +189,100	+512%	+$382K	0.03%	399
2022 Q3	$70K	Sell	36,900 -85,946	-70%	-$179K	0.01%	562
2022 Q2	$259K	Buy	+122,846	New	+$317K	0.02%	465

Other funds holding CGTX

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Perigon Wealth Management's CGTX Position: Q4 2023 in Review

Perigon Wealth Management sold out of Cognition Therapeutics (CGTX) in Q4 2023, closing a stake of 223,500 shares — an estimated $322K sold.

Perigon Wealth Management first reported a position in CGTX in Q2 2022 and held it in 6 quarters. The position peaked at $475K in Q4 2022. 37 funds tracked by Wall St. Rank hold CGTX as of Q4 2023.

Perigon Wealth Management reported no remaining Cognition Therapeutics position as of Q4 2023 after selling out during the quarter.
Perigon Wealth Management sold 223,500 Cognition Therapeutics shares in Q4 2023, an estimated $322K.
Perigon Wealth Management first reported a position in Cognition Therapeutics in Q2 2022 and held it in 6 quarters.
Perigon Wealth Management's Cognition Therapeutics position peaked at $475K in Q4 2022.
37 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2023.

Based on Perigon Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.